Accueil   Diary - News   All news Poxel signs Strategic Acquisition Agreement with DeuteRx

Poxel signs Strategic Acquisition Agreement with DeuteRx

 

  • Poxel acquires exclusive, worldwide ownership to DRX-065 (deuterium-stabilized R-pioglitazone), a clinical stage program being pursued for the treatment of NASH

 

  • Additional programs, including deuterated drug candidates for metabolic, specialty and rare diseases, also acquired from DeuteRx

 

  • Poxel plans to advance PXL770 and DRX-065, two differentiated product candidates with unique and complementary mechanisms of action, into proof-of-concept studies for the treatment of NASH in 2019

 

 

LYON, France, & ANDOVER, Mass.--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), and DeuteRx LLC, a privately-held clinical-stage biopharmaceutical company dedicated to improving racemic drugs, today announced that Poxel has acquired DRX-065, a novel clinical stage drug candidate that the company plans to develop for the treatment of NASH. Poxel has also acquired a portfolio of additional deuterated drug candidates from DeuteRx for metabolic, specialty and rare diseases.

 

Read the full press release